The ideal goal of CD8+ TEXs reinvigoration is to boost anti-tumor immunity as much as possible, without causing immune-related tissue damage, prolong survival, suppress terminal exhaustion differentiation and contribute to the achievement of tumor elimination and better clinical outcomes in cancer patients. This evidence concerns the gene CD8A and neoplasm.